Estramustine binding protein and anti-proliferative effect of estramustine in human glioma cell lines.
Four human cell lines derived from malignant gliomas were immunohistochemically examined for their content of estramustine-binding protein (EMBP). EMBP was detected in a large amount in all glioma cells during the entire cell cycle. EMBP has previously been demonstrated to be the major receptor protein in prostatic cancers for the cytostatic drug estramustine-phosphate (EMP). EMP caused a dose-dependent inhibition of exponentially growing cells by increasing the number of cells in G2/M stage of the cell cycle as monitored by flow cytofluorometry. The effect may be coupled to arrest of the glioma cells at metaphase. The presence of EMBP may suggest a selective binding and effect of EMP in glioma cells.
D002352:Carrier Proteins / Q000032:analysis*; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D004961:Estramustine / Q000494:pharmacology*; D005910:Glioma / Q000032:analysis* / Q000473:pathology; D006801:Humans; D007124:Immunoenzyme Techniques; D009363:Neoplasm Proteins / Q000032:analysis*; D009588:Nitrogen Mustard Compounds / Q000494:pharmacology*; D029584:Prostatic Secretory Proteins; D014407:Tumor Cells, Cultured / Q000032:analysis / Q000187:drug effects
D002352:Carrier Proteins; D009363:Neoplasm Proteins; D009588:Nitrogen Mustard Compounds; D029584:Prostatic Secretory Proteins; C028321:estramustine-binding protein; D004961:Estramustine